Patents Assigned to Tri-Institutional Therapeutics Discovery Institute
-
Patent number: 11964960Abstract: The various examples presented herein are directed to compounds of the formula A-L1-Het1-L2-Cy1 or a pharmaceutical acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: A is cycloalkyl, aryl, arylalkyl or heterocyclyl; Het1 is heterocyclyl containing at least two heteroatoms; Cy1 is a heterocyclyl; L1 is a bond, alkyl, alkenyl or alkynyl linker; L2 is an acyl or alkyl linker; and A and Cy1 are different. The compounds are useful in the treatment of fibrotic diseases, abnormal vascular leak and pathological angiogenesis.Type: GrantFiled: March 8, 2019Date of Patent: April 23, 2024Assignees: Cornell University, Tri-Institutional Therapeutics Discovery InstituteInventors: Timothy Hla, Irina Jilishitz, Peter Meinke, Andrew Stamford, Michael Foley, Ayumu Sato, Yasufimi Wada, Yoshiyuki Fukase, Asato Kina, Hiroki Takahagi, Hideyuki Igawa, William J. Polvino
-
Publication number: 20240115721Abstract: It is an object of the present invention to provide an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody-drug conjugate or the pharmaceutical composition, and the like. The present invention provides an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.Type: ApplicationFiled: January 13, 2022Publication date: April 11, 2024Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITEDInventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
-
Publication number: 20240115720Abstract: The present invention provides a novel anti-DLL3 antibody-pyrrolodiazepine derivative and a novel anti-DLL3 anti-body-pyrrolodiazepine derivative conjugate using the same.Type: ApplicationFiled: January 13, 2022Publication date: April 11, 2024Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITEDInventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
-
Patent number: 11834515Abstract: The compounds of the present invention are represented by the following compounds having Formula I and Formula (I?): where the substituents R1, R2, R2?, R3, R4, R5, R?, R?, X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R?, R?, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.Type: GrantFiled: October 11, 2018Date of Patent: December 5, 2023Assignees: CORNELL UNIVERSITY, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTEInventors: Gang Lin, Carl Nathan, Laura Kirkman, Wenhu Zhan, Trevor Morgan, Kenjiro Sato, Ryoma Hara, Masanori Kawasaki, Toshihiro Imaeda, Akinori Toita, Rei Okamoto, Takafumi Yukawa, Kazuyoshi Aso, Tzu-Tshin Wong, John D. Ginn, Michael A. Foley
-
Patent number: 11732005Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I?): where the substituents R, R1, R3, R4, R, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R1, R2, R3, R4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.Type: GrantFiled: November 8, 2021Date of Patent: August 22, 2023Assignees: CORNELL UNIVERSITY, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTEInventors: Gang Lin, Carl Nathan, Wenhu Zhan, Trevor Morgan, Ryoma Hara, Toshihiro Imaeda, Rei Okamoto, Kenjiro Sato, Kazuyoshi Aso, Tzu-Tshin Wong, Michael A. Foley
-
Publication number: 20220213211Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target CD371 and cells comprising such CD371-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the CD371-targeted antigen-recognizing receptors for treatment.Type: ApplicationFiled: March 11, 2022Publication date: July 7, 2022Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Anthony Daniyan, Renier J. Brentjens, Ivo C. Lorenz, Mary Ann Pohl
-
Publication number: 20220195064Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to CD371 and methods of using such antibodies or antigen-binding fragments thereof same.Type: ApplicationFiled: March 11, 2022Publication date: June 23, 2022Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Anthony Daniyan, Renier J. Brentjens, Ivo C. Lorenz, Mary Ann Pohl
-
Patent number: 10981899Abstract: Provided are 6-amino substituted 2,6-diamino-4-chloropyrimidine compounds which are specific inhibitors of soluble adenylyl cyclase. The compounds can be formulated with pharmaceutical carriers and used for reducing cyclic AMP levels. The compositions can be used for treatment of various conditions including ocular hypotony.Type: GrantFiled: April 28, 2017Date of Patent: April 20, 2021Assignees: Cornell University, Tri-Institutional Therapeutics Discovery InstituteInventors: Jochen Buck, Lonny Levin, Lavoisier Ramos-Espiritu, Clemens Steegborn, Ayumu Sato, Rei Okamoto, Mayako Michino